CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Lupin Atlantis Holdings S.A. v. InvaGen Pharmaceuticals Inc.

1:16-cv-00708

Overview

Case Number 1:16-cv-00708
Filing Date 2016-08-11
Status Terminated
Termination Date 2017-07-06
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

InvaGen Pharmaceuticals Inc. Operating Company

Represented By

5 Attorneys Listed

Salvatore Guerriero

Email: sguerriero@crbcp.com

Robert S. Silver

Email: rsilver@langergrogan.com

Pei-Ru Wey

Email: Peiru.Wey@offitkurman.com

Lynne Terrebonne

Email: lynn.terrebonne@offitkurman.com

R. Touhey Myer

Kratz & Barry LLP

Tel: +1 (302) 527-8378

800 N. West Street, Wilmington, DE 19801

Plaintiff

Lupin Atlantis Holdings S.A. Operating Company

Represented By

7 Attorneys Listed

Megan C. Haney

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

Linnea P. Cipriano

Email: lcipriano@goodwinlaw.com

Emily L. Rapalino

Email: erapalino@goodwinlaw.com

Elizabeth J. Holland

Email: Elizabeth.Holland@allenovery.com

Christopher J. Morten

Email: cmorten@goodwinlaw.com

Brigid M. Morris

UNDELIVERABLE EMAIL 5/7/2019

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 2 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (2): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8026281
Treating metabolic syndrome with fenofibrate
Filed: 2005-04-22
Issued: 2011-09-27
Expired (Term Ended)
Expires: 2025-04-22
US9314447
Reduced dose pharmaceutical compositions of fenofibrate
Filed: 2013-04-01
Issued: 2016-04-19
Active (6.5 yrs remaining) +60d PTA
Expires: 2033-05-31

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

4

Dispositive

0

Granted

0

Denied

0

Pending / Review

4

Motions by Category

Claim Construction / Markman Filing 4

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Pending / Under Review
CLAIM CONSTRUCTION OPENING BRIEF filed by Lupin Atlantis Holdings S.A.. (Phillips, John) (Entered: 04/21/2017)
Entry #43 • 2017-04-21 Document →
Claim Construction / Markman Filing Pending / Under Review
DECLARATION re 43 Claim Construction Opening Brief [Declaration of Christopher J. Morten, Esq.] by Lupin Atlantis Holdings S.A.. (Attachments: # 1 Exhibit A, # ...
Entry #44 • 2017-04-21 Document →
Claim Construction / Markman Filing Pending / Under Review
CLAIM Construction Chart by Lupin Atlantis Holdings S.A.. (Phillips, John) (Entered: 03/17/2017)
Entry #39 • 2017-03-17 Document →
Claim Construction / Markman Filing Pending / Under Review
SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Case referred to the Magistrate Judge for discovery and all motions to...
Entry #20 • 2016-11-17 Document →

Docket Entries

(80 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFINGEMENT filed against InvaGen Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1978574.)- filed by Lupin Atlantis Holdings S.A.(Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(aah) (Entered: 08/12/2016)

Entry #1 • 2016-08-11
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (aah) (Entered: 08/12/2016)

Entry #2 • 2016-08-11
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 07/04/2016. Date of Expiration of Patent: See attached form.Thirty Month Stay Deadline:01/04/2019. (aah) (Main Document 3 replaced on 8/12/2016) (sec). (Entered: 08/12/2016)

Entry #3 • 2016-08-11
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,026,281; 9,314,447; (aah) (Entered: 08/12/2016)

Entry #4 • 2016-08-11
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin Ltd. for Lupin Atlantis Holdings S.A. filed by Lupin Atlantis Holdings S.A.. (aah) (Entered: 08/12/2016)

Entry #5 • 2016-08-11
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc